Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 06, 2023

Long-Term Outcomes After Neoadjuvant Pembrolizumab Based on Pathological Response in Patients With Resectable Stage III/IV Cutaneous Melanoma

Annals of Oncology


Additional Info

Annals of Oncology
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma
Ann. Oncol 2023 Jul 04;[EPub Ahead of Print], CE Sharon, GN Tortorello, KL Ma, AC Huang, X Xu, LR Giles, S McGettigan, K Kreider, LM Schuchter, AJ Mathew, RK Amaravadi, PA Gimotty, JT Miura, GC Karakousis, TC Mitchell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading